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B-cell chronic lymphocytic B-cell chronic lymphocytic leukemia followed by mycosis leukemia followed by mycosis fungoides in a psoriatic patient fungoides in a psoriatic patient on long-term methotrexate on long-term methotrexate therapy therapy Sir, A 69-year-old man with a medical history of diabetes mellitus and hypertension had plaque-type psoriasis since he was 48 years old. He had previously been treated with topical corticosteroids, salicylic acid, calcipotriol and acitretin. He had been on methotrexate 15 mg weekly since 2008 with good results with monitoring for side effects by routine blood tests (serum chemistry, hematology and urinalysis) every 3-6 months. On routine investigations in December 2011, he was found to have a high total leukocyte count (50.4 × 10 3 /μl) with lymphocytosis (45.6 × 10 3 /μl). A hematologic referral was sought and in the presence of >5000 B-lymphocytes/ ml in the peripheral blood for a duration of more than 3 months and identification of a clonal B-cell population on flow cytometry, a diagnosis of B-cell chronic lymphocytic leukemia was made. At that time, the patient was diagnosed with asymptomatic early-stage disease (Binet Stage A with hemoglobin ≥10 g/dl, platelets ≥100 10 9 /L) with only the cervical lymph nodes being involved. Methotrexate therapy 15 mg/ week was continued till late 2013 with good control of psoriasis when it was stopped by the patient himself with a rapid flare of psoriasis. The patient presented to us in October 2014 with erythematosquamous plaques over the trunk and limbs. On examination, there were multiple infiltrated erythematous scaly plaques over the trunk and extremities [ Figures 1-3 ] with a single brightly erythematous nodule of size 10 mm × 6 mm, over his right cheek [ Figure 4 ], Skin biopsy from the nodule of the right cheek and the right arm showed a conspicuous lymphocytic infiltrate in the superficial and deep dermis characterized by small-sized T-lymphocytes with some epidermotropism [ Figure 5a With a diagnosis of psoriasis with mycosis fungoides, we started the patient on psoralen plus ultraviolet A therapy while for B-chronic lymphocytic leukemia, he was given mono-chemotherapy with cyclophosphamide.
Psoriasis is estimated to affect 2-3% of the population worldwide. 1 Mycosis fungoides is the most common variant of primary cutaneous T-cell lymphoma accounting for almost 50% of all primary cutaneous lymphomas. 2 It most commonly affects middle-aged and elderly adults of all races. 2 Typically, neoplastic T-cells localize in the skin and patients present with patches, plaques, tumors or erythroderma. Mycosis fungoides is generally an indolent malignancy with slow progression over years or even decades. 2 Tumors develop only in about 10% of cases. Lymphadenopathy is usually a late occurrence and visceral dissemination (lungs, spleen, liver, gastrointestinal tract) only rarely develops. Extracutaneous dissemination is directly correlated to the extent of cutaneous disease. 2 Chronic lymphocytic leukemia is a member of the non-Hodgkin lymphoma family and represents a study demonstrated that psoriasis is associated with an increased risk of lymphoma and the association is strongest for Hodgkin lymphoma and cutaneous T-cell lymphoma. Increasing severity of disease predicted increased risk. 1 The involvement of various inflammatory cell subsets in the pathogenesis of psoriasis and the lack of immune surveillance potentially induced by classical immunosuppressive antipsoriatic treatments such as methotrexate and cyclosporine are the main factors which might explain the development of cutaneous lymphomas in psoriatic patients on immunosuppressive agents. 4, 5 The question of whether psoriasis is associated with an increased risk of lymphoma is still a matter of controversy. A recent large population-based cohort Drug-related lymphomas are mainly B-lineage neoplasms associated with the presence of Epstein-Barr virus in the neoplastic lymphoid cells. 6 A study investigating the frequency of malignant neoplasms in 248 psoriatic patients treated with long-term methotrexate and followed up for a mean period of 7 years concluded that methotrexate does not seem to contribute to the development of malignant neoplasms in this group. 7 However, in a more recent large study, exposure to high doses of methotrexate, as was the case in our patient, was the only therapeutic exposure associated with a higher risk of lymphoma among patients with psoriasis initially treated with psoralen plus ultraviolet A. 8 The occurrence of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia, is very unusual and there are only a few previous case reports and small series. The distinction between a true neoplastic disorder (mycosis fungoides) and a reactive process remains difficult especially because of the similarities in histopathology in these two entities. The distinction thus relies on a constellation of clinical findings (patch/ plaques for true mycosis fungoides, papules for pseudo-mycosis fungoides), course of evolution and T cell clonal rearrangement studies all of which may also be unable to differentiate them in some cases. 9 Several hypotheses have been put forth to explain the co-occurrence of cutaneous T cell lyphoma in patients with chronic lymphocytic leukemia. One hypothesis supposes that cutaneous lymphomas could derive from precursor stem cells residing in extracutaneous compartments such as bone marrow. Secondly, the neoplastic B-cells and/or their environment may promote the development of a T-cell lymphoproliferation. In addition, certain patients may be predisposed because of an underlying genetic disposition or because of their medical history, including malignancies, exposure to viruses or treatment of the preexisting lymphoproliferative disease. 10 Given the rarity of concomitant cutaneous T-cell lymphoma and chronic lymphocytic leukemia, it is difficult to know if the association between these two forms of lymphoma might influence their development and progression. 10 
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